• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Co-infection with an atypical pathogen of COVID-19 in a young.

作者信息

Chen Fu-Lun, Wang Cheng-Hui, Hung Ching-Sheng, Su Ying-Shih, Lee Wen-Sen

机构信息

Division of Infectious Disease, Department of Internal Medicine, Wan Fang Medical Center, Taipei Medical University, Taipei, Taiwan; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.

Department of Laboratory Medicine, Wan Fang Medical Center, Taipei Medical University, Taipei, Taiwan; Pulmonary Research Center, Wan Fang Medical Center, Taipei Medical University, Taipei, Taiwan; School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.

出版信息

J Microbiol Immunol Infect. 2021 Feb;54(1):154-155. doi: 10.1016/j.jmii.2020.05.007. Epub 2020 May 21.

DOI:10.1016/j.jmii.2020.05.007
PMID:32505530
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7241350/
Abstract
摘要

相似文献

1
Co-infection with an atypical pathogen of COVID-19 in a young.一名年轻人中新冠病毒与非典型病原体的合并感染。
J Microbiol Immunol Infect. 2021 Feb;54(1):154-155. doi: 10.1016/j.jmii.2020.05.007. Epub 2020 May 21.
2
Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.近期文献不支持将羟氯喹与阿奇霉素联合用于新冠肺炎患者。
Int J Antimicrob Agents. 2021 Jan;57(1):106174. doi: 10.1016/j.ijantimicag.2020.106174.
3
Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.羟氯喹和阿奇霉素对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒载量的影响尚不确定。
Int J Antimicrob Agents. 2021 Jan;57(1):106169. doi: 10.1016/j.ijantimicag.2020.106169.
4
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.参考研究：《羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果》
Int J Antimicrob Agents. 2021 Jan;57(1):106176. doi: 10.1016/j.ijantimicag.2020.106176.
5
Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".致编辑的信：关于“羟氯喹和阿奇霉素作为治疗新型冠状病毒肺炎的药物：一项开放标签非随机临床试验的结果”
Int J Antimicrob Agents. 2021 Jan;57(1):106171. doi: 10.1016/j.ijantimicag.2020.106171.
6
Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".关注“羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果”的临床结局。
Int J Antimicrob Agents. 2021 Jan;57(1):106175. doi: 10.1016/j.ijantimicag.2020.106175.
7
Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.羟氯喹啉与阿奇霉素联合治疗COVID-19患者的安全性概况。
Int J Antimicrob Agents. 2021 Jan;57(1):106236. doi: 10.1016/j.ijantimicag.2020.106236.
8
Can we use hydroxychloroquine to treat COVID-19 now?我们现在可以使用羟氯喹治疗新冠病毒疾病吗？
Int J Antimicrob Agents. 2021 Jan;57(1):106173. doi: 10.1016/j.ijantimicag.2020.106173.
9
Doxycycline as an Alternative to Azithromycin in Elderly Patients.多西环素作为老年患者阿奇霉素的替代药物
Int J Antimicrob Agents. 2021 Jan;57(1):106168. doi: 10.1016/j.ijantimicag.2020.106168.
10
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.羟氯喹和阿奇霉素对新型冠状病毒肺炎患者严重急性呼吸综合征冠状病毒2清除率的影响：一项荟萃分析
Int J Antimicrob Agents. 2021 Jan;57(1):106240. doi: 10.1016/j.ijantimicag.2020.106240.

引用本文的文献

1
Clinical Features of Long COVID Patients Coinfected With .新冠长期症状患者合并感染……的临床特征
Can J Infect Dis Med Microbiol. 2024 Dec 7;2024:7213129. doi: 10.1155/cjid/7213129. eCollection 2024.
2
Tendency in Pulmonary Aspergillosis Investigation during the COVID-19 Era: What Is Changing?COVID-19 时代肺部曲霉菌病研究趋势：有何变化？
Int J Environ Res Public Health. 2022 Jun 9;19(12):7079. doi: 10.3390/ijerph19127079.
3
Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges.宿主对SARS-CoV-2反应动力学的主要见解：影响与挑战
Front Microbiol. 2021 Aug 25;12:637554. doi: 10.3389/fmicb.2021.637554. eCollection 2021.
4
COVID-19 associated with pulmonary aspergillosis: A literature review.COVID-19 相关肺曲霉病：文献综述。
J Microbiol Immunol Infect. 2021 Feb;54(1):46-53. doi: 10.1016/j.jmii.2020.09.004. Epub 2020 Sep 24.

本文引用的文献

1
Treatment options for COVID-19: The reality and challenges.治疗 COVID-19 的选择：现实与挑战。
J Microbiol Immunol Infect. 2020 Jun;53(3):436-443. doi: 10.1016/j.jmii.2020.03.034. Epub 2020 Apr 4.
2
Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens.SARS-CoV-2 与其他呼吸道病原体的合并感染率。
JAMA. 2020 May 26;323(20):2085-2086. doi: 10.1001/jama.2020.6266.
3
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
4
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.中国武汉严重 COVID-19 患者的临床病程和结局：一项单中心、回顾性、观察性研究。
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
5
Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV.人畜共患冠状病毒带来的新威胁——从非典、中东呼吸综合征到2019新型冠状病毒。
J Microbiol Immunol Infect. 2020 Jun;53(3):365-367. doi: 10.1016/j.jmii.2020.02.001. Epub 2020 Feb 4.
6
Recommendations and guidelines for the treatment of pneumonia in Taiwan.台湾肺炎治疗建议与指南。
J Microbiol Immunol Infect. 2019 Feb;52(1):172-199. doi: 10.1016/j.jmii.2018.11.004. Epub 2018 Dec 6.